YSB (HKG:9885) recorded a 258% rise in attributable profit in the first half of 2025 to 78.1 million yuan from 21.8 million yuan in the year-ago period, a Wednesday Hong Kong bourse filing said.
Earnings per share were 0.11 yuan in the half year, up from 0.03 yuan in the corresponding period of the last year.
The pharmaceutical retailer's revenue rose 12% to 9.84 billion yuan in the interim period from 8.81 billion yuan a year prior.
The higher revenue was supported by the development of the company's self-operation business wing and an acquisition that injected fresh momentum into its revenue growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.